BR112014004182A2 - métodos para tratar a hepatite c, para tratamento contra o vírus da hepatite c, e para prevenir ou tratar a hepatite c, e, composição - Google Patents
métodos para tratar a hepatite c, para tratamento contra o vírus da hepatite c, e para prevenir ou tratar a hepatite c, e, composiçãoInfo
- Publication number
- BR112014004182A2 BR112014004182A2 BR112014004182A BR112014004182A BR112014004182A2 BR 112014004182 A2 BR112014004182 A2 BR 112014004182A2 BR 112014004182 A BR112014004182 A BR 112014004182A BR 112014004182 A BR112014004182 A BR 112014004182A BR 112014004182 A2 BR112014004182 A2 BR 112014004182A2
- Authority
- BR
- Brazil
- Prior art keywords
- hepatitis
- treating hepatitis
- treating
- virus
- preventing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161526798P | 2011-08-24 | 2011-08-24 | |
US201161529358P | 2011-08-31 | 2011-08-31 | |
US201261617813P | 2012-03-30 | 2012-03-30 | |
PCT/US2012/052216 WO2013028953A1 (en) | 2011-08-24 | 2012-08-24 | Combination treatments for hepatitis c |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014004182A2 true BR112014004182A2 (pt) | 2017-03-14 |
Family
ID=47746891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014004182A BR112014004182A2 (pt) | 2011-08-24 | 2012-08-24 | métodos para tratar a hepatite c, para tratamento contra o vírus da hepatite c, e para prevenir ou tratar a hepatite c, e, composição |
Country Status (17)
Country | Link |
---|---|
US (1) | US20140234253A1 (pt) |
EP (1) | EP2747569A4 (pt) |
JP (2) | JP2014527061A (pt) |
KR (1) | KR20140065427A (pt) |
CN (1) | CN103917095A (pt) |
AU (1) | AU2012298750A1 (pt) |
BR (1) | BR112014004182A2 (pt) |
CA (1) | CA2845321A1 (pt) |
CL (1) | CL2014000428A1 (pt) |
CO (1) | CO6890100A2 (pt) |
CR (1) | CR20140086A (pt) |
EA (1) | EA201490254A1 (pt) |
HK (1) | HK1198869A1 (pt) |
IL (1) | IL230844A0 (pt) |
MX (1) | MX2014002171A (pt) |
SG (1) | SG2014010490A (pt) |
WO (1) | WO2013028953A1 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8344155B2 (en) * | 2009-09-04 | 2013-01-01 | Glaxosmith Kline Llc | Chemical compounds |
PE20141391A1 (es) * | 2011-08-17 | 2014-10-29 | Glaxosmithkline Llc | Combinacion que comprende un compuesto con actividad antiviral y un agente terapeutico |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
TW201600087A (zh) | 2011-10-21 | 2016-01-01 | 艾伯維有限公司 | 治療c型肝炎病毒(hcv)的方法 |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
DK2583677T1 (da) | 2011-10-21 | 2015-01-19 | Abbvie Inc | Fremgangsmåder til behandling af HCV omfattende mindst to direktevirkende antivirale midler, ribavirin, men ikke inteferon |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
ES2623287T3 (es) | 2013-04-12 | 2017-07-10 | Achillion Pharmaceuticals, Inc. | Derivado de nucleósido altamente activo para el tratamiento del VHC |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
ES2680550T3 (es) * | 2013-07-09 | 2018-09-10 | Bristol-Myers Squibb Company | Combinaciones de inhibidores del virus de la hepatitis C |
CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
WO2015096674A1 (zh) * | 2013-12-23 | 2015-07-02 | 南京圣和药业股份有限公司 | 丙型肝炎病毒抑制剂及其应用 |
EP3091010A4 (en) * | 2013-12-31 | 2017-10-04 | Nanjing Sanhome Pharmaceutical Co., Ltd. | 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene hepatitis c virus inhibitor and application thereof |
WO2015109445A1 (zh) * | 2014-01-21 | 2015-07-30 | 杭州普晒医药科技有限公司 | 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途 |
US20170312297A1 (en) * | 2014-11-10 | 2017-11-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | Long Acting Pharmaceutical Compositions For Hepatitis C |
MA41812A (fr) * | 2015-03-27 | 2018-01-30 | Janssen Pharmaceuticals Inc | Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc |
WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
CN110693887B (zh) * | 2019-05-17 | 2022-06-17 | 歌礼药业(浙江)有限公司 | 包含索磷布韦和拉维达韦的片剂及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100158862A1 (en) * | 2006-08-11 | 2010-06-24 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US8303944B2 (en) * | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI480272B (zh) * | 2008-10-09 | 2015-04-11 | Anadys Pharmaceuticals Inc | 藉由5,6-二氫-1h-吡啶-2-酮與一或多種其他抗病毒化合物的組合物抑制c型肝炎病毒的方法 |
US8729077B2 (en) * | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
RU2011127080A (ru) * | 2009-01-07 | 2013-02-20 | Сайнексис, Инк. | Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич |
MX360800B (es) * | 2009-05-13 | 2018-11-16 | Gilead Pharmasset Llc Star | Compuestos antivirales. |
US8344155B2 (en) * | 2009-09-04 | 2013-01-01 | Glaxosmith Kline Llc | Chemical compounds |
US8415374B2 (en) * | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
US8377980B2 (en) * | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP2013514982A (ja) * | 2009-12-18 | 2013-05-02 | イデニク プハルマセウティカルス,インコーポレイテッド | 5,5−縮合アリーレン又はヘテロアリーレンc型肝炎ウイルス阻害剤 |
WO2012040126A1 (en) * | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
-
2012
- 2012-08-24 WO PCT/US2012/052216 patent/WO2013028953A1/en active Application Filing
- 2012-08-24 US US14/240,420 patent/US20140234253A1/en not_active Abandoned
- 2012-08-24 BR BR112014004182A patent/BR112014004182A2/pt not_active IP Right Cessation
- 2012-08-24 CN CN201280052257.0A patent/CN103917095A/zh active Pending
- 2012-08-24 KR KR1020147007736A patent/KR20140065427A/ko not_active Application Discontinuation
- 2012-08-24 JP JP2014527322A patent/JP2014527061A/ja active Pending
- 2012-08-24 MX MX2014002171A patent/MX2014002171A/es unknown
- 2012-08-24 SG SG2014010490A patent/SG2014010490A/en unknown
- 2012-08-24 CA CA2845321A patent/CA2845321A1/en not_active Abandoned
- 2012-08-24 EA EA201490254A patent/EA201490254A1/ru unknown
- 2012-08-24 AU AU2012298750A patent/AU2012298750A1/en not_active Abandoned
- 2012-08-24 EP EP12826268.0A patent/EP2747569A4/en not_active Withdrawn
-
2014
- 2014-02-06 IL IL230844A patent/IL230844A0/en unknown
- 2014-02-21 CL CL2014000428A patent/CL2014000428A1/es unknown
- 2014-02-24 CR CR20140086A patent/CR20140086A/es unknown
- 2014-02-26 CO CO14040944A patent/CO6890100A2/es unknown
- 2014-12-16 HK HK14112612.7A patent/HK1198869A1/xx unknown
-
2017
- 2017-04-20 JP JP2017083252A patent/JP2017165746A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CO6890100A2 (es) | 2014-03-10 |
HK1198869A1 (en) | 2015-06-19 |
EA201490254A1 (ru) | 2014-07-30 |
WO2013028953A1 (en) | 2013-02-28 |
CL2014000428A1 (es) | 2014-08-01 |
US20140234253A1 (en) | 2014-08-21 |
CA2845321A1 (en) | 2013-02-28 |
EP2747569A1 (en) | 2014-07-02 |
IL230844A0 (en) | 2014-03-31 |
SG2014010490A (en) | 2014-04-28 |
EP2747569A4 (en) | 2015-07-08 |
CR20140086A (es) | 2014-05-02 |
AU2012298750A1 (en) | 2014-03-13 |
MX2014002171A (es) | 2014-04-25 |
KR20140065427A (ko) | 2014-05-29 |
JP2014527061A (ja) | 2014-10-09 |
JP2017165746A (ja) | 2017-09-21 |
CN103917095A (zh) | 2014-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014004182A2 (pt) | métodos para tratar a hepatite c, para tratamento contra o vírus da hepatite c, e para prevenir ou tratar a hepatite c, e, composição | |
BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
BR112013020425A2 (pt) | composições e métodos para o tratamento ou prevenção de infecção por vírus da hepatite b | |
BR112014023937A2 (pt) | composição farmacêutica, agente farmacêutico de combinação e método de tratamento | |
ZA201404061B (en) | Compositions and methods for treating the hepatitis c virus | |
PL2672966T3 (pl) | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania | |
BR112014009528A2 (pt) | métodos e composições para tratar eritropoiese ineficaz | |
BR112014025726A2 (pt) | mecanismo, sistema e método para tratamento endodôntico | |
BR112014013246A8 (pt) | composição catalisadora, e, método para tratar nox | |
BR112014004181A2 (pt) | composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia | |
PT2729151T (pt) | Composição farmacêutica, métodos de tratamento e suas utilizações | |
BR112013018679A2 (pt) | agente para o tratamento da alopecia | |
BR112015010501A2 (pt) | composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada | |
BR112014004192A2 (pt) | composição de tratamento de sementes, e, método de tratamento de sementes | |
BR112013010738A2 (pt) | composto, composição farmacêutica, e, método para tratar uma infecção viral | |
BR112014007963A2 (pt) | aminotiazoles substituídos como inibidores de cãncer, incluindo carcinoma hepatocelular, e como inibidores da replicação do vírus da hepatite | |
BR112014031896A2 (pt) | composto, composição farmacêutica, e, método para o tratamento de um distúrbio | |
BR112014025339A8 (pt) | método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo. | |
BR112014031512A2 (pt) | composição cosmética e método para o tratamento cosmético. | |
BR112014003556A2 (pt) | método de tratamento de vírus, e, composição farmacêutica | |
BR112013029514A2 (pt) | composição imunogênica, vacina, e, método de tratar ou impedir uma doença | |
BR112014015549A8 (pt) | composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção | |
BRPI0924398A2 (pt) | perexilina, metodo de tratamento de hfnef e programa de tratamento para tratar hfnef | |
FI20115078A0 (fi) | Maanpeitekate, katteen käsittelyaine ja menetelmä maanpeitekatteen valmistamiseksi ja katteen ja käsittelyaineen käyttö | |
BR112014003003A2 (pt) | compostos, respectivos usos e processos para tratar ou prevenir infecção viral |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2529 DE 25-06-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |